Exclusive special offer and discount title banner vector image

ASIA-PACIFIC DRY EYE DISEASE MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Asia-Pacific Dry Eye Disease Market by Type (OTC, Prescription) Market by Product (Anti-inflammatory Drugs (Cyclosporine, Corticosteroid, Other Anti-inflammatory Drugs), Artificial Tears, Punctal Plugs, Secretagogues, Other Products) Market by Distribution Channel (Hospital Pharmacies, Independent Pharmacies and Drugstores, Online Pharmacies) by Geography


MARKET OVERVIEW

The Asia-Pacific dry eye disease market is expected to record a CAGR of 5.60% during the forecast period, 2023-2032, and is projected to garner a revenue of $1987.33 million by 2032.

The dry eye disease market growth in Asia-Pacific is attributed to the rapidly growing aging population in countries like China. Also, the Asian population is evaluated to be more vulnerable to dry eye disease, projecting severe symptoms, than other ethnic groups. However, the Asia-Pacific dry eye disease market growth is hindered by limited healthcare access.

To Know More About This Report, Request a Free Sample Copy

The Asia-Pacific dry eye disease market growth analysis includes the assessment of Thailand, Indonesia, China, Australia & New Zealand, India, Japan, South Korea, and Rest of Asia-Pacific. Japan, a major innovation-driven country with regard to healthcare, encompasses consistency and higher awareness & willingness associated with healthcare enhancement. As per two cross-sectional population-based studies evaluating the epidemiological aspect of dry eye disease (DED), Japan’s prevalence of DED was higher compared to other countries in 2017. Also, many studies have evaluated the burden of costs related to DED. The work productivity loss per patient associated with definite DED was between $741 and $6160. This results in a significant economic burden. Such factors, alongside government initiatives, R&D initiatives, and technological advancements, are estimated to propel Japan’s dry eye disease market demands. 

In Indonesia, dry eye disease is prevalent among the senior population with cataracts. A study on the prevalence of dry eye disease (DED) and its subtypes in the aging population before cataract surgery found that half of the respondents displayed dry eye symptoms. They were categorized as preclinical dry eye or having dry eye disease, whereas more than one-quarter were predisposed to dry eye. 

The study thus highlights the prevalence of DED in the geriatric population, which is increasingly vulnerable to inadequate tear production due to diminished corneal sensation, altered reflex secretion, lacrimal gland dysfunction, or inflammatory destruction of lacrimal glands. Moreover, oxidative stress and inflammation, which increase with old age, play a major role in dry eye development in the elderly. Such aspects define the aspects of the Indonesia dry eye disease market. 

The Asia-Pacific dry eye disease market segmentation includes distribution channel, product, and type. The distribution channel segment includes online pharmacies, independent pharmacies and drugstores, and hospital pharmacies. 

Online pharmacies are a well-established distribution method, gaining gradual acceptance in emerging markets and extensively researched in developed countries. The demand for a vast variety of products sold online has increased rapidly due to the increasing penetration of the internet. Accordingly, the development of online services, self-medication using over-the-counter trends, and growing internet use have expanded online pharmacies’ sales. In addition, the increasing awareness regarding primary care and prescription drugs is projected to benefit the segment’s growth. 

Furthermore, virtual healthcare is becoming increasingly popular as healthcare technology advances. As a result, pharmacies are enhancing their online services. Most medications prescribed for dry eye disease are drops, and these drops can be purchased online. Besides, during the pandemic, people preferred purchasing from online pharmacies instead of visiting congested stores.

Some of the leading companies operating in the Asia-Pacific dry eye disease market include Santen Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, OASIS Medical, etc.

Santen Pharmaceutical Co Ltd focuses on the marketing, manufacturing, and research & development of medical devices and pharmaceutical products. It operates through its group of companies located in the United States, Europe, and Asia. The product portfolio includes prescription ophthalmic products for glaucoma, diabetic retinopathy, myopia, dry eye, cataract, retinal detachment, etc. The company has its headquarters in Kita-ku, Osaka, Japan. 

One of its key products, IKERVIS®, is used to treat adults with severe keratitis. It contains ciclosporin.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Distribution Channel, Product, Type
Countries AnalyzedThailand, Indonesia, China, Australia & New Zealand, India, Japan, South Korea, and Rest of Asia-Pacific
Companies AnalyzedAFT Pharmaceuticals, Alcon, Allergan Plc (Acquired by AbbVie), Bausch Health Companies Inc, Johnson & Johnson, Lumenis, Novaliq GmbH, Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co Ltd, Santen Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, VISUfarma

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
      2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
      3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
      4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE 
      2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE 
      3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
    2. KEY RESTRAINTS
      1. RISK OF SIDE EFFECTS
      2. SUBSTITUTE THERAPIES
      3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
  4. KEY ANALYTICS
    1. PARENT MARKET ANALYSIS
    2. KEY MARKET TRENDS
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET MATURITY ANALYSIS
    6. MARKET CONCENTRATION ANALYSIS
    7. VALUE CHAIN ANALYSIS
      1. RESEARCH AND DEVELOPMENT
      2. MANUFACTURING
      3. DISTRIBUTORS
      4. POST-SALES MONITORING
  5. MARKET BY TYPE
    1. OTC
    2. PRESCRIPTION
  6. MARKET BY PRODUCT
    1. ANTI-INFLAMMATORY DRUGS
      1. CYCLOSPORINE
      2. CORTICOSTEROID
      3. OTHER ANTI-INFLAMMATORY DRUGS
    2. ARTIFICIAL TEARS
    3. PUNCTAL PLUGS
    4. SECRETAGOGUES
    5. OTHER PRODUCTS
  7. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACIES
    2. INDEPENDENT PHARMACIES AND DRUGSTORES
    3. ONLINE PHARMACIES
  8. GEOGRAPHICAL ANALYSIS
    1. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
      3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
      4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        2. JAPAN
          1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        5. INDONESIA
          1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        7. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        8. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. AFT PHARMACEUTICALS
      2. ALCON
      3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
      4. BAUSCH HEALTH COMPANIES INC
      5. JOHNSON & JOHNSON
      6. LUMENIS
      7. NOVALIQ GMBH
      8. NOVARTIS AG
      9. OASIS MEDICAL
      10. OTSUKA PHARMACEUTICAL CO LTD
      11. SANTEN PHARMACEUTICAL CO LTD
      12. SENTISS PHARMA PRIVATE LIMITED
      13. SUN PHARMACEUTICAL INDUSTRIES LTD
      14. TEVA PHARMACEUTICAL INDUSTRIES LTD
      15. VISUFARMA

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – DRY EYE DISEASE

TABLE 2: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK

TABLE 13: KEY PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET

TABLE 14: LIST OF MERGERS & ACQUISITIONS

TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: VALUE CHAIN ANALYSIS

FIGURE 7: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 8: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022

FIGURE 11: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022

FIGURE 13: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 21: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 25: CHINA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: JAPAN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: INDIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 28: SOUTH KOREA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 29: INDONESIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: THAILAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 31: VIETNAM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 32: AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FAQ’s